title: Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS.
abstract: OBJECTIVE
  The aim of this study was to evaluate the hemodynamic effects of octreotide in patients treated with transjugular intrahepatic portosystemic stent shunt in relation to plasma levels of octreotide and glucagon and the correlation between portal pressure and noninvasive Doppler parameters.
  
  
  METHODS
  In 15 fasting patients, we i.v. administered isotonic sodium chloride followed by octreotide 25 microg/h and 100 microg/h, each over 1 h. We measured portal pressure (PP) directly and portal vein blood flow velocity by Doppler ultrasound simultaneously and calculated portal vascular resistance (PVR) and portal venous flow (PVF). Blood samples were taken for glucagon and octreotide (mean +/- SE).
  
  
  RESULTS
  Octreotide reduced PP (120': -7.7+/-2.2%, p < 0.01 vs baseline; 180': - 11.4+/-2.1%, p < 0.01 vs baseline) and PVF (120': -21.7+/-31.7%, p < 0.01 vs baseline; 180': -11.6+/-18.1%, p < 0.05 vs baseline). Glucagon decreased with the increase in octreotide levels and showed a correlation with the decrease in PP and with PVF. In patients with a high PVR, we found a close inverse correlation between PP and portal vein blood flow velocity (r = -0.83, p = 0.03) as well as Cl (r = 0.81, p = 0.05), whereas poor correlation was found in patients with low PVR.
  
  
  CONCLUSIONS
  Octreotide caused a dose-related, moderate but sustained reduction in PP in patients with transjugular intrahepatic portosystemic stent shunt. PVR seems to be an important parameter that influences the efficacy of octreotide and the relation between PP and noninvasive Doppler parameters.
authors.affiliation: Department of General Internal Medicine, University of Bonn, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Schiedermaier
authors.forename: B
authors.initials: B
authors.lastname: Göke
authors.forename: T
authors.initials: T
authors.lastname: Sauerbruch
mesh_terms: D001783:Blood Flow Velocity / Q000187:drug effects; D005260:Female; D005934:Glucagon / Q000097:blood*; D006439:Hemodynamics / Q000187:drug effects; D006490:Hemostatics / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D017082:Portal Pressure / Q000187:drug effects; D011169:Portal Vein / Q000000981:diagnostic imaging; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D013152:Splanchnic Circulation / Q000187:drug effects*; D018608:Ultrasonography, Doppler
chemical_list: D006490:Hemostatics; D005934:Glucagon; D015282:Octreotide